5 programs we will not list

All 5 would pay us to send readers their way. None of them is on the chart. The largest pays $350 a sale.

A new program passes six checks before it gets a chart row or a visit link.

  1. Transparent ownership. A named founder or chief executive, one legal entity, a real published address.
  2. Company age. The company or its domain is older than six months.
  3. Real user base. Review volume we can verify elsewhere, not a self-reported customer count.
  4. Clean reputation. No unresolved action over product safety or quality, no FTC action, no lawsuit over patient harm.
  5. No sibling brand marketing an unapproved drug. The check covers every brand under the same owners, not only the one applying.
  6. Verified first-party pricing. The price we would publish is readable on the program's own page.
4 held off the chart, 1 declined outright. Last reviewed September 4, 2026.
ProgramChecks it failedWhyWhat would change our mind
Oak Weight LossHeld August 20, 2026$350 per sale, approved on the Katalys networkRead from the program's own site and terms
  • Transparent ownership
  • No sibling brand marketing an unapproved drug
One set of terms names three different legal entities. The address is a placeholder and no founder, chief executive or medical director is named on the site. A sibling brand, RetaClinic, markets retatrutide, which the FDA has not approved for any use.One legal entity with a real published address, named leadership, the compounding pharmacies disclosed, and no retatrutide sibling.
TrimiHeld August 22, 2026$200 per sale, approved on the Katalys networkRead from the program's own site and its Trustpilot profile
  • Transparent ownership
  • Real user base
No legal entity and no address are published. The site names medical directors but no owner. Its Trustpilot score fell from 4.6 to about 2.8 across 2026 on a run of refund and account-closure complaints.An entity, an address and a named founder published, and the complaint pattern resolved.
Pallas HealthHeld August 22, 2026$175 per sale, approved on the Katalys networkRead from the WHOIS record and a review search
  • Company age
  • Real user base
The domain was about four and a half months old when we looked, under our six-month floor. We found no review footprint outside the company's own site.Age clears about October 7, 2026. It also needs a review footprint we can verify.
SnagRXHeld August 22, 2026$150 per sale, approved on the Katalys networkRead from the program's own site and a review search
  • Transparent ownership
  • Real user base
The 125,000-customer figure is the company's own. The only review footprint we could verify belongs to Embody, a sibling brand. No founder, chief executive or medical director is named, and the pricing page runs countdown timers.A review footprint of its own plus a named leader on the site.
HealSendDeclined September 4, 2026$150 per qualified lead, offered on the Awin networkRead from its Awin merchant listing on September 3, 2026Declined before the checks were run. The eligibility marketing settled it.The listing says HealSend evaluates eligible patients starting at a BMI of 20 and sells that as more accessible than competing clinics. A BMI of 20 is a healthy weight. Its Awin listing opened eight days before we looked and has never paid a publisher. Its written terms promise about $100 a sale against an invitation promising $150 a lead. Contacts run across the company, an outside agency and a personal Gmail address.Nothing on the current record.

When a program fixes what its row names, we run the six checks again and it goes on the chart at whatever score it earns.

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.